CD4 and neoplasm: A more direct indication of the therapeutically beneficial role of CD4+ T cells in anti-tumor immunity involves studies of neoantigen vaccination based on whole-exome and RNA-seq to identify candidate neoepitopes generated by non-synonymous somatic mutations (based on predicted MHC affinity), followed by immunization with the top candidates.